Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH ALL 2021 | Chemotherapy-free treatment regimens for Ph+ ALL

Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses upcoming and exciting areas in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), including chemotherapy-free regimens. The GIMEMA LAL2116 trial (NCT02744768), evaluating dasatinib and blinatumomab in adult Ph+ ALL, shows very encouraging outcomes in the frontline setting. The combination of blinatumomab plus ponatinib is also being evaluated in a clinical trial (NCT03147612) with the rationale that a more potent tyrosine kinase inhibitor may lead to deeper responses. Data from the trial (NCT03576547) exploring venetoclax plus ponatinib seem promising as well. As the field advances, transplant-free strategies and chemotherapy-free regimens should be explored both in the frontline and relapsed/refractory setting. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.

Disclosures

Consulting fees from AstraZeneca, NGMBio, Jazz Pharmaceuticals.
Research funding from Takeda Oncology and Astellas Pharma Inc.
Honoraria from Amgen and Novartis.